ReviewPediatric nephrology (Berlin, Germany)2026
Calciphylaxis in children: a case series and systematic review.
Review in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calciphylaxis is a rare and life-threatening vascular calcification disorder characterized by occlusion of subcutaneous microvessels and subsequent ischemic skin necrosis. While it is well described in adults, pediatric data remain extremely limited. A systematic literature search was conducted in PubMed, Web of Science, and Embase from inception to January 2026. Studies involving patients ≤18 years old were included. Two additional pediatric cases from our institution were also analyzed. Patient 1 was a 20-month-old girl with end-stage renal disease (ESRD) secondary to a pathogenic WT1 mutation and developed calciphylaxis following low molecular weight heparin calcium injections but survived after sodium thiosulfate (STS) therapy, amputation, and parathyroid ablation. Patient 2, an 11-year-and-8-month-old girl with systemic lupus erythematosus, lupus nephritis, and ESRD, died from sepsis despite intensive treatment. The systematic review included 19 pediatric patients with a mean age of 10.5 ± 6.2 years and a median diagnostic delay of 3 months (IQR, 1-5). ESRD, secondary hyperparathyroidism, and hyperphosphatemia were the most common risk factors. Systemic calcification was present in 47% of cases, and skin biopsy was performed in 68%. Calcium-phosphate control and intravenous STS were the most effective therapeutic modalities for disease reversal based on clinical observations. STS therapy was associated with lower mortality compared with non-STS treatment (12.5% vs. 40.0%; OR = 0.21; 95% CI, 0.01-2.79; P = 0.30), although without statistical significance. The overall calciphylaxis-specific mortality was 26%, rising to 67% in patients showing no clinical response to treatment. Pediatric calciphylaxis predominantly occurs in children with ESRD, hyperphosphatemia, and secondary hyperparathyroidism. Traditional adult risk factors such as diabetes mellitus and warfarin exposure are uncommon. The condition is associated with high mortality, especially in treatment-refractory cases, highlighting the need for early recognition and aggressive multimodal management.
Indexed as
Identifiers
42435048What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.